Drug Profile
Anti-tenascin monoclonal antibody BC-4-I-131
Latest Information Update: 22 Aug 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 17 Nov 1998 Phase-I clinical trials for Glioma in Italy (Intralesional)